Zobrazeno 1 - 10
of 40
pro vyhledávání: '"K Weigang-Köhler"'
Autor:
E. Weidmann, Heike Richly, Lothar Bergmann, K. Weigang-Köhler, Luise Maute, Stefan Fuxius, Iris Burkholder, Lutz Edler, G. Hartung, Bernhard Wörmann, D. Köberle, Jörn Rüssel, B. Moritz, Walter E. Aulitzky, Max E. Scheulen, Gerhard Heil
Publikováno v:
European Journal of Cancer. 51:27-36
Background Pancreatic ductal adenocarcinoma (PDAC) is one of the most common malignant tumours and is still associated with a poor prognosis in advanced disease. To improve the standard therapy with gemcitabine, we initiated a prospective randomised
Autor:
E. Kettner, Joerg Trojan, Florian Lordick, T. Steinmetz, Stefan Boeck, S. Zeuzem, Volker Heinemann, H. Kröning, K. Weigang-Köhler, D. Quietzsch, H. Depenbrock, O. Stotzer, C.-H. Köhne, Martin Fuchs
Publikováno v:
Annals of Oncology. 18:745-751
A standard second-line chemotherapy regimen has yet to be defined for patients with gemcitabine (Gem)-refractory advanced pancreatic cancer (PC).In this multicenter phase II trial, patients with unresectable or metastatic PC who had progressed on sin
Autor:
Patrick Schöffski, K Weigang-Köhler, J. Van den Brande, Pierre Fumoleau, F Reinke, Jan H.M. Schellens, Jantien Wanders, Florence Duffaud, Jan B. Vermorken, Arnaud Roth, R F de Boer
Publikováno v:
British Journal of Cancer
British Journal of Cancer, Vol. 88, No 5 (2003) pp. 648-53
British Journal of Cancer, Vol. 88, No 5 (2003) pp. 648-53
Cancer of the colon and rectum is one of the most frequent malignancies both in the US and Europe. Standard palliative therapy is based on 5-fluorouracil/folinic acid combinations, with or without oxaliplatin or irinotecan, given intravenously. Oral
Autor:
L, Bergmann, L, Maute, G, Heil, J, Rüssel, E, Weidmann, D, Köberle, S, Fuxius, K, Weigang-Köhler, W E, Aulitzky, B, Wörmann, G, Hartung, B, Moritz, L, Edler, I, Burkholder, M E, Scheulen, H, Richly
Publikováno v:
European journal of cancer (Oxford, England : 1990). 51(1)
Pancreatic ductal adenocarcinoma (PDAC) is one of the most common malignant tumours and is still associated with a poor prognosis in advanced disease. To improve the standard therapy with gemcitabine, we initiated a prospective randomised phase-II tr
Autor:
K, Weigang-Köhler
Publikováno v:
MMW Fortschritte der Medizin. 145(11)
Fatigue in tumor patients is caused both by the tumor and/or its treatment, and is accompanied by loss of drive, lack of energy, depressive mood and loss of vitality; it is unresponsive to rest and sleep. A differentiation is made between mental fati
Autor:
O. Mora, K. Weigang-Köhler, Olivia Pagani, Cristiana Sessa, M. Burgess, T. De Pas, R. Johnson, G. Greim, I. Weimer
Publikováno v:
European journal of cancer (Oxford, England : 1990). 38(18)
LY355703 is a synthetic derivative of the marine cryptophycins, cytotoxic agents which induce mitotic arrest by binding at the microtubule vinca binding domain. Promising preclinical features of LY355703 were the 40–400 greater potency than paclita
Autor:
A.-R. Hanauske, Markus Borner, Pierre Fumoleau, A. Amelsberg, A. Ehret, Jantien Wanders, Ch. Dittrich, K Weigang-Köhler, H. Huisman, G. Greim
Publikováno v:
European journal of cancer (Oxford, England : 1990). 38(8)
The pyrimido-pyrimidine BIBX 1382 BS inhibits the intracellular tyrosine kinase domain of the epidermal growth factor receptor (EGFR), thus specifically reverting the aberrant enzymatic activity from overexpressed and constitutively activated EGFR. A
Autor:
Hanno Riess, Marco Niedergethmann, Helmut Oettle, A. Helm, M. Moik, Martina Stauch, K. Zippel, C. Hammer, K. Weigang-Köhler, Ingo G.H. Schmidt-Wolf
Publikováno v:
Journal of Clinical Oncology. 23:LBA4009-LBA4009
LBA4009 Background: The combination of gemcitabine 1 g/m2 and 5-FU 750 mg/m2 as a continuous 24 h-infusion, modulated by folinic acid 200 mg/m2 given on d1, 8, 15, 22 every six weeks (GFF) showed interesting results in a multicenter phase II study (O
Autor:
U. Bruntsch, H. Bouterfa, K. Weigang-Köhler, C. Peschel, J. Buekki, C. Dutreix, G. Greim, M. Heike
Publikováno v:
European Journal of Cancer. 37:S17
Autor:
J. Boni, J. Korth-Bradley, C.J.A. Punt, A. Hanauske, K. Weigang-Köhler, C. Thielert, J. Frisch
Publikováno v:
European Journal of Cancer. 37:S68